Ausgabe 2/2011
Inhalt (24 Artikel)
Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer
Shun-Lai Li, Chia-Hsin Huang, Chih-Chan Lin, Zih-Ning Huang, Jyh-Haur Chern, Hsiao-Yin Lien, Yong-Yi Wu, Chia-Hui Cheng, Chia-Yu Chang, Jiunn-Jye Chuu
Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2
Ponnuraj Nagendraprabhu, Ganapasam Sudhandiran
Inhibitory effects of tea polyphenols by targeting cyclooxygenase-2 through regulation of nuclear factor kappa B, Akt and p53 in rat mammary tumors
Preeti Roy, Jasmine George, Smita Srivastava, Shilpa Tyagi, Yogeshwer Shukla
CYT997 Causes apoptosis in human multiple myeloma
Katherine Monaghan, Tiffany Khong, Gregg Smith, Andrew Spencer
Selective proapoptotic activity of polyphenols from red wine on teratocarcinoma cell, a model of cancer stem-like cell
Tanveer Sharif, Cyril Auger, Christian Bronner, Mahmoud Alhosin, Thibaut Klein, Nelly Etienne-Selloum, Valérie B. Schini-Kerth, Guy Fuhrmann
Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine
Irene V. Bijnsdorp, Reto A. Schwendener, Herbert Schott, Iduna Fichtner, Kees Smid, Adrie C. Laan, Sarah Schott, Nienke Losekoot, Richard J. Honeywell, Godefridus J. Peters
Oleanolic acid derivative Dex-OA has potent anti-tumor and anti-metastatic activity on osteosarcoma cells in vitro and in vivo
Yingqi Hua, Zhiyu Zhang, Jianxin Li, Quan Li, Shuo Hu, Jian Li, Mengxiong Sun, Zhengdong Cai
Lupane Triterpenoids—Betulin and Betulinic acid derivatives induce apoptosis in tumor cells
Harish Kommera, Goran N. Kaluđerović, Jutta Kalbitz, Reinhard Paschke
Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/ β-catenin pathway
Pandurangan Ashokkumar, Ganapasam Sudhandiran
Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes
Tushar S. Basu Baul, Anup Paul, Lorenzo Pellerito, Michelangelo Scopelliti, Palwinder Singh, Pooja Verma, Andrew Duthie, Dick de Vos, Edward R. T. Tiekink
Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4′,5-trimethoxylstilbene-3′-O-phosphate disodium (M410)
Yu-Chen Cai, Yong Zou, Yan-Li Ye, Hong-Yi Sun, Quan-Guan Su, Zhi-Xin Wang, Zhao-Lei Zeng, Li-Jian Xian
Temporal evolution of patient characteristics enrolled on phase I trials
Afshin Dowlati, Madappa Kundranda, Sudhir Manda, Lauren Patrick, Pingfu Fu
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Anne M. Traynor, James P. Thomas, Ramesh K. Ramanathan, Tarak D. Mody, Dona Alberti, George Wilding, Howard H. Bailey
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia
Isam Abdel-Karim, William K. Plunkett Jr, Susan O’Brien, Francis Giles, Deborah Thomas, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Min Du, Karen B. Schneck, Victor J. Chen, Boris K. Lin, Steven J. Nicol, Hagop M. Kantarjian
A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction
Dok Hyun Yoon, Hyo Jung Lee, Yong Sang Hong, Kyu-pyo Kim, Sung Sook Lee, Jae-Lyun Lee, Heung Moon Chang, Min-Hee Ryu, Yoon-Koo Kang, Jung Shin Lee, Tae Won Kim
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer
Qing Zhou, Daniel Gustafson, Sujatha Nallapareddy, Sami Diab, Stephen Leong, Karl Lewis, Lia Gore, Wells A. Messersmith, Anthony M. Treston, S. Gail Eckhardt, Carolyn Sidor, D. Ross Camidge
Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer
Bhuvaneswari Ramaswamy, Ewa Mrozek, John Philip Kuebler, Tanios Bekaii-Saab, Eric H. Kraut
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618
Susanne M. Arnold, James Moon, Stephen K. Williamson, James N. Atkins, Sai-Hong I. Ou, Michael LeBlanc, Susan G. Urba
Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer
Hee Yeon Seo, Hyun Joo Lee, Ok Hee Woo, Kyong Hwa Park, Sang Uk Woo, Dae Sik Yang, Ae-Ree Kim, Jae-Bok Lee, Eun Sook Lee, Yeul Hong Kim, Jun Suk Kim, Jae Hong Seo
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Chul Kim, Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Tae Won Kim, Ho Young Lim, Hye Jin Kang, Young Suk Park, Baek-Yeol Ryoo, Yoon-Koo Kang
A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma
Christopher W. Ryan, Jacqueline Vuky, Joseph S. Chan, Zunqiu Chen, Tomasz M. Beer, Deirdre Nauman
Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma
Daniel J. Luther, Vahagn Ohanyan, Patricia E. Shamhart, Cheryl M. Hodnichak, Hamayak Sisakian, Tristan D. Booth, J. Gary Meszaros, Anupam Bishayee
Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines
Claudio Celeghini, Rebecca Voltan, Erika Rimondi, Valter Gattei, Giorgio Zauli
Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer
Binbing Ling, Lifeng Chen, Jane Alcorn, Baohua Ma, Jian Yang